Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study
Authors:
Open Access
- 1 October 2005
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 106 (7) , 2269-2275
Abstract
The long-term efficacy and toxicity of hydroxyurea for infants are undefined, and its role in preventing organ dysfunction is unknown. Short-term feasibility of hydroxyurea administration, toxicities, hematologic effects, and effect on spleen function in infants with sickle cell anemia (SCA) were reported (Hydroxyurea Safety and Organ Toxicity [HUSOFT] trial). These infants completing 2 years of hydroxyurea therapy (20 mg/kg/d) were offered study extension with dose escalation to 30 mg/kg/d. Patients were monitored with laboratory tests and biannual imaging studies. Hematologic indices were compared with predicted age-specific values and event rates compared with historic rates. All 21 subjects completing the original trial enrolled in the extension study: median age, 3.4 years old (range, 2.6 to 4.4 years); 12 females; 20 with Hb SS, 1 with Hb S/β0-thalassemia. Seventeen patients completed 4 years of hydroxyurea, and 11 completed 6 years. After 4 years, hydroxyurea was associated with increased hemoglobin concentration, percentage of fetal hemoglobin (Hb F), and mean corpuscular volume (MCV) and decreased reticulocytes, white blood cells (WBCs), and platelets (P < .01). Patients experienced 7.5 acute chest syndrome (ACS) events per 100 person-years, compared with 24.5 events per 100 person-years among historic controls (P = .001). Treated patients had better spleen function than expected and improved growth rates. Infants with SCA tolerate prolonged hydroxyurea therapy with sustained hematologic benefits, fewer ACS events, improved growth, and possibly preserved organ function.Keywords
This publication has 47 references indexed in Scilit:
- A case for developing North-South partnerships for research in sickle cell diseaseBlood, 2005
- Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccinationThe Journal of Pediatrics, 2003
- Hydroxyurea-induced splenic regrowth in an adult patient with severe hemoglobin SC diseaseAmerican Journal of Hematology, 2003
- A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemiaThe Journal of Pediatrics, 2001
- Clinical and hematologic effects of hydroxyurea in children with sickle cell anemiaThe Journal of Pediatrics, 1996
- Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell AnemiaNew England Journal of Medicine, 1995
- Sickle Cell Chronic Lung DiseaseMedicine, 1988
- Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.Journal of Clinical Investigation, 1984
- Influence of Sickle Hemoglobinopathies on Growth and DevelopmentNew England Journal of Medicine, 1984
- Post-natal decline of fetal haemoglobin in homozygous sickle cell disease: relationship to parental Hb F levelsBritish Journal of Haematology, 1982